Abstract Details

Title Plasma Neurofilament light levels are increased in people with Radiologically Isolated Syndrome

Topic Multiple Sclerosis

Presentation(s) P1 - Poster Session 1 (9:00 AM-5:00 PM)

Poster/Presentation
Number 321

Objective To assess for differences in plasma neurofilament light (pNfL) in people with radiologically isolated syndrome (pwRIS) vs. healthy controls (HCs), and to correlate pNfL levels with advanced magnetic resonance imaging (MRI) markers in pwRIS.

Background RIS refers to those without typical MS symptoms but characteristic brain lesions on MRI seen in people with MS (pwMS). Early initiation of disease-modifying therapy (DMT) can improve the prognosis of pwMS, but currently, there are no clear evidence-based guidelines as to how to manage pwRIS. We have previously shown that the vast majority of pwRIS show a high proportion of white matter lesions (WMLs) demonstrating the central vein sign (CVS). Previous studies have shown that blood NfL levels in pwMS correlate with MRI measures. We hypothesize that pNfL levels are increased in some pwRIS and correlate with advanced MRI measures.

Design/Methods 14 RIS subjects and 6 HCs underwent 3T brain and cervical spinal cord MRI and had pNfL levels measured on an HD-1 Simoa platform (Quanterix). Student’s t-tests; and Mann-Whitney U-tests were used to assess differences between RIS and HCs.

Results pwRIS had higher levels of pNfL vs. HCs (p<0.05). pwRIS with more than 20 CVS-positive lesions or more than 50 total WMLs had significantly higher pNfL levels vs. HCs.

Conclusions This pilot study is the first to demonstrate that pNfL levels are increased in pwRIS and correlate with the number of CVS-positive lesions and total number of WMLs. Although requiring prospective confirmation in a larger cohort, these findings suggest that pNfL may have prognostic value in identifying those pwRIS who are at high risk of developing MS. Prospective clinical validation is underway to confirm this hypothesis.

Authors/Disclosures
Raphael Schneider, MD (St. Michael'S Hospital) PRESENTER	Dr. Schneider has nothing to disclose.
Koroboshka Brand-Arzamendi (St Michael's Hospital)	No disclosure on file
Timothy Lim	No disclosure on file
	No disclosure on file
Melanie Guenette	No disclosure on file
	No disclosure on file
Raphael Schneider, MD (St. Michael'S Hospital)	Dr. Schneider has nothing to disclose.
Jiwon Oh, MD, FAAN (St Michael's Hospital)	Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. The institution of Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen-Idec. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD-Serono. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca. Dr. Oh has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Oh has received research support from Biogen-Idec. The institution of Dr. Oh has received research support from Roche.

��ɫ��

��ɫ��